Chronic Insomnia Market Growth Projections 2023-2032: DelveInsight Analysis
The Key Chronic Insomnia Companies in the market include - Janssen Research & Development, Takeda, and others.
The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.
DelveInsight's 'Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Some of the key facts of the Chronic Insomnia Market Report:
The Chronic Insomnia market size was valued ~USD 333 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
Among the seven major markets (7MM), the United States represented 67.3% of the total market size for Chronic Insomnia in 2021.
In the 7 MM countries, there will be 5,697,127 cases of chronic insomnia that have been diagnosed as of 2021
Age plays a significant role in how the disease develops. The age group of 20 to 29 years saw the highest number of cases in the US in 2021 with 474,746. Following this, there were 421,996 instances in the US for each of the age groups of 30-39 and 40-49 years
France had the greatest diagnosed prevalence of chronic insomnia among the European nations, with 890,539 cases. Germany came in second with 407,108 cases in 2021
Germany reported 207,625 instances of chronic insomnia in females and 199,483 cases in men among the EU5 nations in 2021
Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others
Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others
The Chronic Insomnia epidemiology based on gender analyzed that Chronic Insomnia is more prominent in females in comparison to males
The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.
Chronic Insomnia Overview
Chronic insomnia is a long-term sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early, occurring at least three times a week for three months or more. It leads to daytime fatigue, impaired concentration, mood disturbances, and reduced quality of life. Causes can include stress, medical conditions, medications, or poor sleep habits.
Get a Free sample for the Chronic Insomnia Market Report:
Chronic Insomnia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Insomnia Epidemiology Segmentation:
The Chronic Insomnia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Chronic Insomnia
Prevalent Cases of Chronic Insomnia by severity
Gender-specific Prevalence of Chronic Insomnia
Diagnosed Cases of Episodic and Chronic Chronic Insomnia
Download the report to understand which factors are driving Chronic Insomnia epidemiology trends @ Chronic Insomnia Epidemiology Forecast
Chronic Insomnia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Insomnia market or expected to get launched during the study period. The analysis covers Chronic Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Insomnia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Insomnia Therapies and Key Companies
Discover more about therapies set to grab major Chronic Insomnia market share @ Chronic Insomnia Treatment Market
Chronic Insomnia Market Drivers
Increasing Prevalence
Personalization of therapies
Chronic Insomnia Market Barriers
Issues with diagnosis and poor knowledge
Use of off-label drugs
High economic burden
Scope of the Chronic Insomnia Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others
Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others
Chronic Insomnia Therapeutic Assessment: Chronic Insomnia current marketed and Chronic Insomnia emerging therapies
Chronic Insomnia Market Dynamics: Chronic Insomnia market drivers and Chronic Insomnia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Chronic Insomnia Unmet Needs, KOL's views, Analyst's views, Chronic Insomnia Market Access and Reimbursement
Table of Contents
1. Chronic Insomnia Market Report Introduction
2. Executive Summary for Chronic Insomnia
3. SWOT analysis of Chronic Insomnia
4. Chronic Insomnia Patient Share (%) Overview at a Glance
5. Chronic Insomnia Market Overview at a Glance
6. Chronic Insomnia Disease Background and Overview
7. Chronic Insomnia Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Insomnia
9. Chronic Insomnia Current Treatment and Medical Practices
10. Chronic Insomnia Unmet Needs
11. Chronic Insomnia Emerging Therapies
12. Chronic Insomnia Market Outlook
13. Country-Wise Chronic Insomnia Market Analysis (2019–2032)
14. Chronic Insomnia Market Access and Reimbursement of Therapies
15. Chronic Insomnia Market Drivers
16. Chronic Insomnia Market Barriers
17. Chronic Insomnia Appendix
18. Chronic Insomnia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Calgary Herald
32 minutes ago
- Calgary Herald
Bank of Canada holds interest rate at 2.75% again as 'uncertainty remains high'
Article content The Bank of Canada decided to hold its interest rate on Wednesday, saying uncertainty remains high and it will continue to assess the impact of U.S. tariffs on the economy. Article content 'The Canadian economy is softer but not sharply weaker. And we've seen some firmness in recent inflation data,' said Bank of Canada governor Tiff Macklem, in prepared remarks in Ottawa. Article content 'Against this backdrop, we decided to hold the policy rate unchanged as we continue to gain more information on U.S. trade policy and its impacts.' Article content Article content Article content On Tuesday, U.S. President Donald Trump signed an executive order doubling tariffs on steel and aluminum from 25 per cent to 50 per cent, with the levies taking effect on Wednesday. Tariffs on Canadian autos, energy and other goods remain in place, although many items are exempted under the Canada–United States–Mexico Agreement (CUSMA). Trade and security negotiations between the U.S. administration and the Canadian government are ongoing. Article content On Wednesday, Macklem singled out inflation in the decision. Headline inflation was 1.7 per cent in April but, excluding the removal of the carbon tax, came in higher than expected at 2.3 per cent. Core inflation — the central bank's preferred measure when making its monetary policy decisions — also heated up. Article content Article content 'There is some unusual volatility in inflation, but these measures suggest underlying inflation could be firmer than we thought,' said Macklem. 'Higher core inflation can be partly attributed to higher goods prices, including food, and may reflect effects of trade disruption.' Article content Growth in the first quarter was also above central bank's expectations, with gross domestic product rising 2.2 per cent. Growth at the beginning of the year was boosted by a surge in Canadian exports to the United States, as businesses raced to beat Trump's tariffs. The central bank expects growth to be considerably weaker in the second quarter.
Globe and Mail
an hour ago
- Globe and Mail
Tesla Sales Plunged in France. What Do Analysts Say About TSLA Stock for June 2025?
Tesla's (TSLA) European operations are experiencing a dramatic downturn, with sales across multiple markets declining sharply despite CEO Elon Musk's claims tht the company has no demand problem. For instance, in France, Tesla's vehicle deliveries declined by 67% year over year to 721 units, the worst monthly performance in three years. This decline occurred even with the refreshed Model Y in full production at Gigafactory Berlin, eliminating previous supply constraints as an excuse for poor performance. The troubling pattern extends across Europe, with Portugal seeing a 68% year-over-year decline despite overall EV sales rising 25%. Denmark, Netherlands, Spain, and Sweden all reported significant double-digit drops, indicating systemic rather than isolated market issues. Tesla Sales Soar in Norway Norway stands as Tesla's sole bright spot in Europe, with sales surging 213% to 2,346 vehicles in May. However, this increase in demand is at least partially tied to aggressive financial incentives, such as interest-free loans and national policies that support EVs, rather than a recovery in organic demand. Political factors are impacting Tesla's brand value in 2025. A Norwegian EV Association survey revealed that 43% of respondents would avoid purchasing Teslas due to political reasons. Further, Musk's support for Germany's far-right AfD party and anti-union stance has sparked protests at European dealerships. Meanwhile, competition continues to intensify as traditional automakers and Chinese manufacturers gain ground. BYD (BYDDY) recently outsold Tesla in pure electric vehicles across Europe for the first time, while established brands like Volkswagen (VWAGY) and Porsche (POAHY) are capturing market share previously held by Tesla. Tesla's attempts to stimulate demand through price cuts and financial incentives across Sweden, Germany, Britain, and France suggest recognition of its weakening competitive position in what was once a growth market. Is TSLA Stock a Good Buy Right Now? Tesla delivered a challenging first quarter, with revenue declining to $19.34 billion, a $1.97 billion year-over-year decrease, while net income dropped to $409 million from $1.39 billion in the prior year period. Despite financial headwinds, Tesla demonstrated operational resilience and maintained a strong balance sheet. It produced approximately 363,000 vehicles and delivered just under 337,000 units during the quarter, executing an industry-first simultaneous production line changeover across all factories for the new Model Y. This ambitious transition resulted in several weeks of lost production but showcased Tesla's advanced operational capabilities. Tesla's energy storage business continues to grow with 10.4 GWh deployed in the first quarter. The EV maker is focused on ramping up production and increasing market penetration in this vertical. However, evolving trade policies pose risks to the energy storage segment. Tesla warned that the ongoing trade war could impact energy generation and storage operations more than its automotive business. Tesla reported an operating cash flow of $2.16 billion and incurred capital expenditures of $1.49 billion. In the year-ago period, its capital expenditures were much higher at $2.78 billion. The company ended Q1 with a cash balance of $37 billion, an increase of $433 million from the end of 2024. What Is the Target Price for TSLA Stock? Tesla faces mounting challenges from macroeconomic pressures, including interest rate fluctuations that affect vehicle financing affordability and intensifying competition as traditional automakers accelerate their adoption of electric vehicles. It continues investing in artificial intelligence, robotics, and autonomous driving capabilities, including the development of the Cybercab robotaxi. Looking ahead, Tesla emphasizes profitable growth through the optimization of existing factories, cost reduction initiatives, and the launch of new models. The next growth phase depends on advances in autonomy, the introduction of next-generation platform vehicles, and vertical integration, including in-house battery cell manufacturing, to improve performance while reducing costs. Out of the 41 analysts covering Tesla stock, 16 recommend 'Strong Buy,' two recommend 'Moderate Buy,' 13 recommend 'Hold,' and 10 recommend 'Strong Sell.' The average target price for TSLA stock is $290, below the current trading price of $344..
Globe and Mail
3 hours ago
- Globe and Mail
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS , June 4, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds. Vinicio Vargas , Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD). Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio. About Ainnova Tech, Inc. Ainnova is a Nevada -based healthtech startup with headquarters in San Jose, Costa Rica , and Houston, Texas . Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: - technologies - ai Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
